Goldman Sachs reinstates coverage on 3M Co. with a Buy rating

Overview

This report is Goldman Sachs's reinstatement-of-coverage company research report on 3M Co. (MMM.N). The report argues that MMM is shifting from an investment narrative dominated by PFAS and Combat Arms litigation liabilities to a self-help improvement story driven by commercial execution, Innovation Acceleration, productivity gains, and balance sheet flexibility.

Core views

The core views are: first, Commercial Excellence and new product introductions will drive improvement in organic growth; second, pricing, productivity, and simplification initiatives will support continued margin expansion in 2026-2027; third, the company still retains some capital deployment capacity even as legal payments continue; fourth, if litigation liabilities are further quantified or resolved, the stock could see valuation re-rating.

Analysis framework

The report combines the company's segment and regional revenue mix, orders and backlog, NPI volume, pricing and productivity bridge, legal cash flow arrangements, capital structure, and peer EV/EBITDA comparisons to form 2026-2028 earnings forecasts and a 12-month target price.

Methodology notes

• Valuation methodEV/EBITDA multiple method

  13.5x Q5-Q8 EBITDA

  Goldman Sachs applies a 13.5x target multiple to its Q5-Q8 EBITDA forecast to derive the 12-month target price of $190.00; this multiple remains below the diversified industrial peer average to reflect lower organic growth and the litigation discount that has not been fully resolved.

• Fundamental frameworkThree-driver self-help improvement framework

  Organic growth, margin expansion, balance sheet flexibility

  The report breaks MMM's upside potential into organic growth improvement from commercial execution and new product introductions, margin expansion from pricing and productivity, and capital allocation flexibility that remains despite litigation payments.

• Relative comparisonGS Factor Profile

  Growth、Financial Returns、Multiple、Integrated

  The Goldman Sachs Factor Profile compares stocks across growth, financial returns, valuation multiples, and integrated percentile rankings, providing context for a stock's positioning versus the broader market and industry peers.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 3M Co. (MMM.N)

  Core covered name; Goldman Sachs reinstated Buy rating

  Strengths

  Improved commercial execution, accelerated NPI, productivity programs, pricing power, and lower leverage together support a fundamental recovery.

  Weaknesses

  Historical organic growth has lagged diversified industrial peers, the business mix is complex, and PFAS, Combat Arms, and other product liabilities continue to create a valuation discount.

  Comparison

  The report states MMM trades at about a 4-5 turn discount to ITW on 2027E EBITDA; Goldman Sachs believes this discount is too wide given the backdrop of improving growth and margins.

  Risks

  Legal liabilities come in above expectations, execution on organic growth or margins falls short, capital returns are constrained, and investors continue to assign a litigation discount.

Key data

• Rating and target priceBuy; 12-month target price $190.00; current price $158.32; upside 20.0%Cover-page information shows Goldman Sachs reinstated the Buy rating.
• EPS forecast2026E EPS $8.80; 2027E EPS $9.80; 2028E EPS $10.60Upon reinstating coverage, it revised 2026 EPS from the previous $11.10 to $8.80 and provided 2027/2028 forecasts for the first time.
• Valuation basis13.5x Q5-Q8 EBITDAThe target multiple is below the peer average to reflect the litigation discount and lower organic growth.
• 2025 regional revenueAmericas 55% (of which U.S. 44%), Asia-Pacific 28%, EMEA 17%This shows the company's revenue has globally diversified characteristics.
• 2025 segment revenueSafety and Industrial 46%; Transportation and Electronics 34%; Consumer 20%Safety and Industrial is the largest segment by revenue and EBIT contribution.
• 2026 segment growth expectationsSafety and Industrial +4.8%; Transportation and Electronics +2.7%; Consumer +0.6%Goldman Sachs expects stronger growth in industrial and safety-related businesses.
• Self-help growth contributionAbout 60bps above macro in 2025, about $150mn in revenue; self-help initiatives contribute about 40%/55% of organic growth in 2026/2027In 2025, commercial execution contributed about 75% of above-macro growth.
• New product introductions284 new products in 2025; about 350 in 2026E; about 370 in 2027E; 2027 vitality target about 20%Innovation Acceleration is viewed as a key source of faster organic growth in 2026-2027.
• Margin outlook2026E EBIT growth of more than about $350mn, margin expansion of about 50bps; 2027E operating margin 25.3%Goldman Sachs expects about 140bps of expansion in 2027 versus 2025, above consensus by about 100bps.
• Productivity gainsAbout $550mn in 2025; about $615mn in 2026EGains come from areas including G&A, supply chain, IT simplification, indirect procurement, manufacturing processes, supplier efficiency, and logistics.
• Legal liabilitiesPFAS Public Water Suppliers about $12.5bn/13 years; Combat Arms $6bn/2023-2029; accrued liabilities on the balance sheet about $10.6bnAFFF personal injury and similar matters remain unquantified residual risks.
• Capital flexibilityAvailable capital of about $7.9bn over the next two years, including about $2.0bn from the 15% stake in Solventum; net debt/EBITDA about 0.8xGoldman Sachs believes leverage is below the typical investment-grade industry range of 2.0x-2.5x.
• Data center opportunityCurrent revenue about $600mn, about 2.5% of 2025 sales; potential incremental revenue of about more than $90-$100mnIncludes products such as power infrastructure, Twinax copper cable, and expanded beam optics.

Impact & implications

If the report's view plays out, MMM's investment case will no longer revolve solely around litigation discounting, but will be driven more by improving organic growth, margin recovery, and free cash flow capability. For investors, the key is to verify whether self-help improvement can continue translating into orders, revenue, margins, and capital returns, while monitoring whether litigation liabilities become further clarified.

Risks

• PFAS, Combat Arms, or other product liability outcomes exceed accrued amounts and market expectations, potentially limiting free cash flow and capital returns.
• Organic growth fails to accelerate, Commercial Excellence benefits fade, NPI contribution materializes more slowly than expected, or demand in Transportation and Electronics and Consumer remains weak.
• Tariffs, raw materials, FX, stranded costs, or reinvestment offset pricing and productivity gains, resulting in weaker-than-expected margin expansion.
• Higher legal cash outflows, M&A spending, or a conservative balance sheet policy constrain buybacks and other capital returns.
• Even if operations improve, investors may continue assigning a valuation discount because of unresolved litigation liabilities.

What to watch

• Whether organic growth in 2Q 2026 can clearly exceed 3%, and whether orders and backlog continue converting into revenue.
• The pace of new product launches in 2026-2027, improvement in vitality, and NPI's contribution to revenue growth.
• Whether pricing, productivity, and simplification projects can deliver about $615mn of productivity gains in 2026 and a 25.3% operating margin in 2027.
• Legal developments related to PFAS, AFFF personal injury, state and sovereign environmental claims, site remediation, and potential settlement size.
• The pace of capital deployment, including buybacks, M&A, disposal of the Solventum stake, and changes in net debt/EBITDA.
• Whether revenue growth from data-center-related products and optical interconnect capacity expansion create additional growth contribution.